Anavex Life Sciences (AVXL) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NovaBridge Biosciences (NBP) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 78.2% versus a loss of 85.4%. Over five years, AVXL leads with a -92.7% price change compared with -98.1% for NBP. NovaBridge Biosciences is the larger company by market cap ($146.2 million vs $121.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | NBP |
|---|---|---|
| Share price | $1.31 | $1.26 |
| Market cap | $121.43M | $146.16M |
| 1-day change | -11.49% | -2.33% |
| YTD return | -63.20% | -68.34% |
| 1-year return | -85.41% | -78.16% |
| 5-year return | -92.66% | -98.13% |
| EPS (TTM) | $-0.14 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-46.38M | $-46.27M |
| 52-week high | $9.50 | $5.97 |
| 52-week low | $1.30 | $1.26 |
| Distance from 52-week high | -86.21% | -78.89% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +614.29% |
| Average volume | 1.01M | 390.05K |
| Shares outstanding | 92.70M | 116.00M |
| Employees | 34 | 30 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Healthcare · Biotechnology · 34 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
AVXL vs NBP FAQ
Which is bigger, Anavex Life Sciences or NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $146.16M compared with $121.43M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or NBP?
NBP returned -78.16% over the past 12 months, compared with -85.41% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.